億帆醫藥(002019.SZ)：子公司將在研產品F-627在德國的獨家經銷權許可給APOGEPHA公司
格隆匯2月28日丨億帆醫藥(002019.SZ)公佈，2022年2月28日，公司控股子公司Evive Biotechnology Singapore pte.ltd.，(“新加坡億一”或“甲方”)與Apogepha Arzneimittel GmbH, (“APOGEPHA 公司”或“乙方”)簽訂了《獨家許可協議》，協議約定新家坡億一同意將在研產品艾貝格司亭α注射液(“F-627” )在德國的獨家經銷權許可給APOGEPHA公司 ，APOGEPHA公司負責F-627在德國區域的市場規劃及銷售，為此APOGEPHA公司需要向新加坡億一支付不可退還的40萬美元預付款、最高不超過100萬美元開發里程碑付款及最高不超過3750萬美元的銷售里程碑付款。
APOGEPHA公司是德國一家歷史悠久且擁有高度競爭力的家族製藥企業，總部位於德累斯頓。公司專注於泌尿外科和泌尿腫瘤科治療領域，在創新產品的開發、生產和銷售方面擁有專業的技術和豐富的經驗。APOGEPHA公司致力於為醫療專業人員提供科學前沿的產品，持續為患者帶來更好的治療選擇。其產品目前已實現在全球25個市場銷售，在超過20個國家擁有營銷和分銷合作伙伴，市場主要分部在歐洲、中東及亞洲。此次雙方協議的簽署，有利於擴大APOGEPHA公司在腫瘤學領域的產品組合，為更多CIN患者提供更優質的選擇。
此次協議的簽署，是F-627海外市場繼希臘、塞浦路斯之後的第二個獨家許可協議，標誌着F-627海外市場商業化合作的穩步推進。此次F-627產品獲得歐洲關鍵市場的高度認可，凸顯了F-627的商業化價值，是公司踐行以大分子生物藥敲開歐美主流藥品市場大門的具體實踐，作為全球創新藥物的提供者，公司將繼續推進創新產品的研發工作，持續打造成熟優秀的創新產品，致力於為全球100多個國家或地區的70億人口，提供具有競爭力的創新產品。
未來，公司將藉助APOGEPHA公司在德國深耕多年積累的廣覆蓋的銷售渠道和客户資源，快速打開F-627在德國的市場，提高F-627在德國甚至全球的影響力和市佔率，惠及全球更多CIN患者；此外，億一生物與APOGEPHA公司還將繼續探討在現有合作基礎上擴大歐盟其他高價值區域內的商業合作機會。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
